{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,2]],"date-time":"2026-07-02T00:11:46Z","timestamp":1782951106257,"version":"3.54.5"},"reference-count":25,"publisher":"BMJ","issue":"2","license":[{"start":{"date-parts":[[2021,2,13]],"date-time":"2021-02-13T00:00:00Z","timestamp":1613174400000},"content-version":"unspecified","delay-in-days":12,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"Shanghai Cell Therapy Group Corporation","award":["BZ1903"],"award-info":[{"award-number":["BZ1903"]}]},{"name":"Major National Science and Technology Projects, China","award":["2018ZX10302207-003; 2019YFC1316202"],"award-info":[{"award-number":["2018ZX10302207-003; 2019YFC1316202"]}]}],"content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["J Immunother Cancer"],"accepted":{"date-parts":[[2020,11,20]]},"published-print":{"date-parts":[[2021,2]]},"abstract":"<jats:p>Epithelial ovarian cancer (EOC) is the leading cause of death among gynecological malignancies in China. In particular, advanced\/refractory ovarian cancer lacks effective targeted therapies due to the immunosuppressive and proangiogenic tumor microenvironment. Mesothelin (MSLN) has been found to be highly expressive in most EOC. Targeting MSLN by antibodies or chimeric antigen receptor-modified T (CAR-T) cells and immune checkpoint blockades as well as apatinib, an anti-angiogenic drug, have been used in patients with refractory ovarian cancer. Apatinib was reported to promote the infiltration of CD8<jats:sup>+<\/jats:sup> T cells in lung cancer. However, the combination therapy of CAR-T secreting anti-PD-1 antibody with apatinib in EOC has not been reported.<\/jats:p>\n               <jats:sec>\n                  <jats:title>Case presentation<\/jats:title>\n                  <jats:p>Here we report a case of refractory EOC in a patient who had relapsed after multiline chemotherapy. The patient received autologous T cells that contained sequences encoding single-chain variable fragments specific for MSLN and full-length antibody for PD-1 (\u03b1PD-1). The modified T cells were called \u03b1PD-1-mesoCAR-T cells. After infusion, the copy number and PD-1 antibody secretion of the CAR-T cells were increased in the blood. By application of multimodality tumor tracking, MRI of the liver showed shrinkage of metastatic nodules from average diameter of 71.3\u201339.1\u2009mm at month 2. The patient achieved partial response and survived more than 17 months. IL-6 levels in the patient fluctuated from the baseline to 2\u20134-folds after treatment, but side effects were mild with only grade 1 hypertension and fatigue.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusion<\/jats:title>\n                  <jats:p>\u03b1PD-1-mesoCAR-T cell therapy combined with apatinib demonstrates a potential therapeutic effect on advanced refractory ovarian cancer.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Trial registration number<\/jats:title>\n                  <jats:p>\n                     <jats:ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" ext-link-type=\"clintrialgov\" xlink:href=\"NCT03615313\">NCT03615313<\/jats:ext-link>.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1136\/jitc-2020-001162","type":"journal-article","created":{"date-parts":[[2021,2,15]],"date-time":"2021-02-15T13:25:11Z","timestamp":1613395511000},"page":"e001162","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":48,"title":["\u03b1PD-1-mesoCAR-T cells partially inhibit the growth of advanced\/refractory ovarian cancer in a patient along with daily apatinib"],"prefix":"10.1136","volume":"9","clinical-trial-number":[{"clinical-trial-number":"nct03615313","registry":"10.18810\/clinical-trials-gov"}],"author":[{"given":"Juemin","family":"Fang","sequence":"first","affiliation":[{"name":"Department of Medical Oncology, Shanghai Tenth People\u2019s Hospital, Tongji University Cancer Center, School of Medicine, Tongji University, Shanghai 200072, China"},{"name":"Department of Oncology, Shanghai Dermatology Hospital, Tongji University, Shanghai 200072, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Na","family":"Ding","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Shanghai Tenth People\u2019s Hospital, Tongji University Cancer Center, School of Medicine, Tongji University, Shanghai 200072, China"},{"name":"Cell Drug Business Unit, Shanghai Cell Therapy Group Corporation, Shanghai 201805, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xianling","family":"Guo","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Shanghai Tenth People\u2019s Hospital, Tongji University Cancer Center, School of Medicine, Tongji University, Shanghai 200072, China"},{"name":"Department of Oncology, Shanghai Dermatology Hospital, Tongji University, Shanghai 200072, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yan","family":"Sun","sequence":"additional","affiliation":[{"name":"Cell Drug Business Unit, Shanghai Cell Therapy Group Corporation, Shanghai 201805, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhiwei","family":"Zhang","sequence":"additional","affiliation":[{"name":"Cell Drug Business Unit, Shanghai Cell Therapy Group Corporation, Shanghai 201805, China"},{"name":"Department of Oncology, Affiliated Hospital of Hebei University of Engineering, Handan 056002, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bailu","family":"Xie","sequence":"additional","affiliation":[{"name":"Cell Drug Business Unit, Shanghai Cell Therapy Group Corporation, Shanghai 201805, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhong","family":"Li","sequence":"additional","affiliation":[{"name":"Cell Drug Business Unit, Shanghai Cell Therapy Group Corporation, Shanghai 201805, China"},{"name":"Shanghai Cell Therapy Research Institute, Shanghai Mengchao Cancer Hospital, Shanghai University, Shanghai 201805, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hui","family":"Wang","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Shanghai Tenth People\u2019s Hospital, Tongji University Cancer Center, School of Medicine, Tongji University, Shanghai 200072, China"},{"name":"Department of Oncology, Shanghai Dermatology Hospital, Tongji University, Shanghai 200072, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wei","family":"Mao","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Shanghai Tenth People\u2019s Hospital, Tongji University Cancer Center, School of Medicine, Tongji University, Shanghai 200072, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhicai","family":"Lin","sequence":"additional","affiliation":[{"name":"Cell Drug Business Unit, Shanghai Cell Therapy Group Corporation, Shanghai 201805, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fei","family":"Qin","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Shanghai Tenth People\u2019s Hospital, Tongji University Cancer Center, School of Medicine, Tongji University, Shanghai 200072, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Min","family":"Yuan","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Shanghai Tenth People\u2019s Hospital, Tongji University Cancer Center, School of Medicine, Tongji University, Shanghai 200072, China"},{"name":"Department of Oncology, Shanghai Dermatology Hospital, Tongji University, Shanghai 200072, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wenqi","family":"Chu","sequence":"additional","affiliation":[{"name":"Cell Drug Business Unit, Shanghai Cell Therapy Group Corporation, Shanghai 201805, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Huanlong","family":"Qin","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Shanghai Tenth People\u2019s Hospital, Tongji University Cancer Center, School of Medicine, Tongji University, Shanghai 200072, China"},{"name":"Department of Oncology, Shanghai Dermatology Hospital, Tongji University, Shanghai 200072, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qijun","family":"Qian","sequence":"additional","affiliation":[{"name":"Cell Drug Business Unit, Shanghai Cell Therapy Group Corporation, Shanghai 201805, China"},{"name":"Shanghai Cell Therapy Research Institute, Shanghai Mengchao Cancer Hospital, Shanghai University, Shanghai 201805, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qing","family":"Xu","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Shanghai Tenth People\u2019s Hospital, Tongji University Cancer Center, School of Medicine, Tongji University, Shanghai 200072, China"},{"name":"Department of Oncology, Shanghai Dermatology Hospital, Tongji University, Shanghai 200072, China"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"239","published-online":{"date-parts":[[2021,2,15]]},"reference":[{"key":"2025100301081264000_9.2.e001162.1","doi-asserted-by":"publisher","DOI":"10.3322\/caac.21559"},{"key":"2025100301081264000_9.2.e001162.2","first-page":"937","article-title":"Diagnosis and management of ovarian cancer","volume":"93","author":"Doubeni","year":"2016","journal-title":"Am Fam Physician"},{"key":"2025100301081264000_9.2.e001162.3","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2017.01850","article-title":"Chimeric antigen receptors T cell therapy in solid tumor: challenges and clinical applications","volume":"8","author":"Mirzaei","year":"2017","journal-title":"Front Immunol"},{"key":"2025100301081264000_9.2.e001162.4","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-14-0337"},{"key":"2025100301081264000_9.2.e001162.5","doi-asserted-by":"publisher","DOI":"10.1038\/sj.bjc.6604964"},{"key":"2025100301081264000_9.2.e001162.6","doi-asserted-by":"crossref","first-page":"476","DOI":"10.1038\/s41419-019-1711-1","article-title":"Modified CAR T cells targeting membrane-proximal epitope of mesothelin enhances the antitumor function against large solid tumor","volume":"10","author":"Zhang","year":"2019","journal-title":"Cell Death Dis"},{"key":"2025100301081264000_9.2.e001162.7","doi-asserted-by":"crossref","first-page":"471","DOI":"10.1016\/j.ccell.2019.09.006","article-title":"Combination immunotherapy with CAR T cells and checkpoint blockade for the treatment of solid tumors","volume":"36","author":"Grosser","year":"2019","journal-title":"Cancer Cell"},{"key":"2025100301081264000_9.2.e001162.8","doi-asserted-by":"publisher","DOI":"10.1038\/nbt.4195"},{"key":"2025100301081264000_9.2.e001162.9","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-17-0867"},{"key":"2025100301081264000_9.2.e001162.10","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1358\/dot.2015.51.4.2320599","article-title":"Apatinib: a promising oral antiangiogenic agent in the treatment of multiple solid tumors","volume":"51","author":"Scott","year":"2015","journal-title":"Drugs Today"},{"key":"2025100301081264000_9.2.e001162.11","doi-asserted-by":"crossref","DOI":"10.1016\/j.lfs.2019.117106","article-title":"Therapeutic potentials of apatinib in cancer treatment: possible mechanisms and clinical relevance","volume":"241","author":"Fathi Maroufi","year":"2020","journal-title":"Life Sci"},{"key":"2025100301081264000_9.2.e001162.12","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(19)30723-8"},{"key":"2025100301081264000_9.2.e001162.13","doi-asserted-by":"crossref","first-page":"canimm.0640.2017","DOI":"10.1158\/2326-6066.CIR-17-0640","article-title":"Low-dose apatinib optimizes tumor microenvironment and potentiates antitumor effect of PD-1\/PD-L1 blockade in lung cancer","volume":"7","author":"Zhao","year":"2019","journal-title":"Cancer Immunol Res"},{"key":"2025100301081264000_9.2.e001162.14","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-18-2484"},{"key":"2025100301081264000_9.2.e001162.15","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/j.cellimm.2018.04.007","article-title":"Engineered CAR T cells targeting mesothelin by piggyBac transposon system for the treatment of pancreatic cancer","volume":"329","author":"He","year":"2018","journal-title":"Cell Immunol"},{"key":"2025100301081264000_9.2.e001162.16","doi-asserted-by":"publisher","DOI":"10.1158\/2159-8290.CD-15-0583"},{"key":"2025100301081264000_9.2.e001162.17","doi-asserted-by":"publisher","DOI":"10.1007\/s00262-018-2281-2"},{"key":"2025100301081264000_9.2.e001162.18","doi-asserted-by":"crossref","first-page":"1088","DOI":"10.1080\/15384047.2018.1491500","article-title":"Successful maintenance therapy with apatinib inplatinum-resistant advanced ovarian cancer and literature review","volume":"19","author":"Jin","year":"2018","journal-title":"Cancer Biol Ther"},{"key":"2025100301081264000_9.2.e001162.19","doi-asserted-by":"crossref","first-page":"286","DOI":"10.1016\/j.ygyno.2017.12.013","article-title":"A phase II study of apatinib in patients with recurrent epithelial ovarian cancer","volume":"148","author":"Miao","year":"2018","journal-title":"Gynecol Oncol"},{"key":"2025100301081264000_9.2.e001162.20","doi-asserted-by":"publisher","DOI":"10.1146\/annurev-med-062315-120245"},{"key":"2025100301081264000_9.2.e001162.21","doi-asserted-by":"publisher","DOI":"10.1136\/bmjopen-2017-019321"},{"key":"2025100301081264000_9.2.e001162.22","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdz135"},{"key":"2025100301081264000_9.2.e001162.23","doi-asserted-by":"publisher","DOI":"10.1158\/2326-6066.CIR-13-0170"},{"key":"2025100301081264000_9.2.e001162.24","doi-asserted-by":"crossref","first-page":"1257","DOI":"10.1016\/j.jcyt.2014.05.022","article-title":"Anti-leukemic potency of piggyBac-mediated CD19-specific T cells against refractory Philadelphia chromosome-positive acute lymphoblastic leukemia","volume":"16","author":"Saito","year":"2014","journal-title":"Cytotherapy"},{"key":"2025100301081264000_9.2.e001162.25","doi-asserted-by":"crossref","first-page":"1883","DOI":"10.1016\/j.ymthe.2018.05.007","article-title":"PiggyBac-Engineered T cells expressing CD19-specific cars that lack IgG1 Fc spacers have potent activity against B-ALL xenografts","volume":"26","author":"Bishop","year":"2018","journal-title":"Mol Ther"}],"updated-by":[{"DOI":"10.1136\/jitc-2020-001162corr1","type":"correction","label":"Correction","source":"publisher","updated":{"date-parts":[[2023,1,27]],"date-time":"2023-01-27T00:00:00Z","timestamp":1674777600000}}],"container-title":["Journal for ImmunoTherapy of Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/jitc-2020-001162","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,3]],"date-time":"2025-10-03T08:08:19Z","timestamp":1759478899000},"score":1,"resource":{"primary":{"URL":"https:\/\/jitc.bmj.com\/lookup\/doi\/10.1136\/jitc-2020-001162"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,2]]},"references-count":25,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2021,2,15]]},"published-print":{"date-parts":[[2021,2]]}},"alternative-id":["10.1136\/jitc-2020-001162"],"URL":"https:\/\/doi.org\/10.1136\/jitc-2020-001162","relation":{},"ISSN":["2051-1426"],"issn-type":[{"value":"2051-1426","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,2]]}}}